Insulin therapy for type 2 diabetes: premixed or basal-prandial?

Area of Science:

• Endocrinology
• Metabolic Disorders
• Pharmacology

Background:

• Type 2 diabetes management often requires insulin therapy.
• Basal insulin is a common starting point, but may not prevent disease progression.
• Controlling both fasting and postprandial hyperglycemia is crucial for glycemic control.

Purpose of the Study:

• To evaluate the efficacy of different insulin therapy regimens for type 2 diabetes.
• To propose an optimized, step-by-step insulin treatment strategy.
• To highlight potential biases in industry-sponsored comparative studies.

Main Methods:

• Review of existing literature and clinical guidelines.
• Analysis of treatment targets for fasting glycemia and HbA1c.
• Discussion of basal-bolus (basal-prandial) versus other insulin regimens.

Main Results:

• Treating to a fasting glucose target below 1.20 g/l can achieve HbA1c near 7%.
• Basal insulin alone may not suffice; multiple injections and addressing postprandial glucose are often necessary.
• A basal-prandial regimen with escalating doses of rapid-acting insulin analogues offers flexible titration.

Conclusions:

• A step-by-step basal-prandial insulin regimen is preferable for type 2 diabetes management.
• Targeting specific glucose levels for each injection facilitates dose adjustment.
• Careful interpretation of comparative insulin therapy studies is warranted due to potential bias.